$RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Healthcare
Sector
Biotechnology
Industry
Najat Khan
CEO
800
Employees
$2.94
Current Price
$1.49B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $130,000.00 | 40,000 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $156,970.84 | 47,956 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $839,830.48 | 246,254 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 8 | $2,108,382.56 | 559,680 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 12 | $3,505,763.50 | 881,063 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Gibson Christopher Director | Sale | 40,000 | $3.25 | $130,000.00 | View Details |
| Mar 17, 2026 | Taylor Ben R Chief Financial Officer | Sale | 7,956 | $3.39 | $26,970.84 | View Details |
| Mar 9, 2026 | Khan Najat Director | Sale | 28,298 | $3.35 | $94,659.64 | View Details |
| Mar 3, 2026 | Borgeson Blake Director | Sale | 170,000 | $3.46 | $588,200.00 | View Details |
| Feb 19, 2026 | Gibson Christopher Director | Sale | 40,000 | $3.46 | $138,400.00 | View Details |
| Feb 18, 2026 | Taylor Ben R Chief Financial Officer | Sale | 13,426 | $3.08 | $41,352.08 | View Details |
| Feb 4, 2026 | Gibson Christopher Director | Sale | 40,000 | $4.12 | $164,800.00 | View Details |
| Feb 3, 2026 | Borgeson Blake Director | Sale | 220,000 | $4.20 | $924,000.00 | View Details |
| Jan 20, 2026 | Gibson Christopher Director | Sale | 40,000 | $4.47 | $178,800.00 | View Details |
| Jan 6, 2026 | Borgeson Blake Director | Sale | 220,000 | $4.36 | $959,200.00 | View Details |
| Jan 5, 2026 | Gibson Christopher Director | Sale | 40,000 | $4.25 | $170,000.00 | View Details |
| Dec 29, 2025 | Taylor Ben R Chief Financial Officer | Sale | 21,383 | $4.18 | $89,380.94 | View Details |
15 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.28
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history